TEST:

CellMax-LBx Liquid Biopsy

CellMax Life's liquid biopsy uses a routine blood sample to profile 73 genes from circulating tumor DNA (ctDNA), to identify and assess actionable genomic alterations. The test uses CellMax Life’s proprietary single-molecule-sequencing SMSEQ™ platform which has a greater than 99.999% specificity and an analytical detection limit of 0.1%. The CellMax-LBx non-invasive blood test is typically less expensive than surgically-obtained tissue biopsies, and is more comfortable -- which is especially important given the stress that cancer and associated treatments already place on patients. The liquid biopsy also overcomes problems of inherent tumor heterogeneity of cancer cells. CellMax-LBx liquid biopsy allows for monitoring as frequently as needed, thus enabling earlier detection of potential cancer recurrence.